Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Non-Current Assets: 2015-2024

Historic Non-Current Assets for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to $551.2 million.

  • Intellia Therapeutics' Non-Current Assets fell 25.76% to $343.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $343.3 million, marking a year-over-year decrease of 25.76%. This contributed to the annual value of $551.2 million for FY2024, which is 82.11% up from last year.
  • Latest data reveals that Intellia Therapeutics reported Non-Current Assets of $551.2 million as of FY2024, which was up 82.11% from $302.6 million recorded in FY2023.
  • Intellia Therapeutics' 5-year Non-Current Assets high stood at $551.2 million for FY2024, and its period low was $59.8 million during FY2020.
  • Moreover, its 3-year median value for Non-Current Assets was $303.3 million (2022), whereas its average is $385.7 million.
  • In the last 5 years, Intellia Therapeutics' Non-Current Assets spiked by 778.12% in 2021 and then tumbled by 42.24% in 2022.
  • Yearly analysis of 5 years shows Intellia Therapeutics' Non-Current Assets stood at $59.8 million in 2020, then surged by 778.12% to $525.2 million in 2021, then plummeted by 42.24% to $303.3 million in 2022, then declined by 0.22% to $302.6 million in 2023, then skyrocketed by 82.11% to $551.2 million in 2024.